

A pilot study to determine whether increasing oxygen flow rate or oxygen percentage through a fixed performance mask relieves breathlessness in patients with cystic fibrosis

Submission date 29/09/2006	Recruitment status Stopped	☐ Prospectively registered
Registration date 29/09/2006	Overall study status Stopped	☐ Protocol
Last Edited 06/10/2011	Condition category Nutritional, Metabolic, Endocrine	☐ Statistical analysis plan
		☐ Results
		☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Andrew M Jones

Contact details

The Manchester Adult Cystic Fibrosis Centre
South Manchester University Hospitals NHS Trust
Wythenshawe Hospital
Southmoor Road
Manchester
United Kingdom
M23 9LT
+44 0161 291 2154
andrew.jones@uhsm.nhs.uk

Additional identifiers

Protocol serial number

N0226167746

Study information

Scientific Title

Study objectives

To compare whether changing oxygen flow or oxygen percentage through a fixed performance mask relieves breathlessness in patients with cystic fibrosis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Nutritional, Metabolic, Endocrine: Cystic fibrosis

Interventions

Cohort of stable CF Patients. Patients will perform a maximal bicycle ergometric exercise test on room air (under supervision of a specialist CF physiotherapist and doctor) to determine work rate & associated peak respiratory flow rate. VAS is assessed each minute to specifically determine degree of breathlessness. Following the exercise test VAS is assessed in recovery.

Patients are rested and randomly assigned one of three exercise tests over two days. These exercise tests use either an increasing oxygen concentration mask (flow rate remains the same). Relief of breathlessness will be determined by VAS scoring.

Added September 2008: trial stopped due to lack of resources.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Increasing oxygen flow rate is beneficial to breathless patients

Key secondary outcome(s)

Not provided at time of registration

Completion date

30/12/2007

Reason abandoned (if study stopped)

Lack of resources

Eligibility

Key inclusion criteria

1. Cystic fibrosis patients aged over 16
2. Clinically stable
3. Able to give informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Not Specified

Key exclusion criteria

Patients having respiratory exacerbation

Date of first enrolment

01/07/2005

Date of final enrolment

30/12/2007

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

The Manchester Adult Cystic Fibrosis Centre

Manchester

United Kingdom

M23 9LT

Sponsor information

Organisation

Record Provided by the NHSTCT Register - 2006 Update - Department of Health

Funder(s)

Funder type

Government

Funder Name

South Manchester University Hospitals NHS Trust (UK), NHS R&D Support Funding

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration